logo
Not just sugar: The long-term impacts of Type2 diabetes you cannot afford to ignore

Not just sugar: The long-term impacts of Type2 diabetes you cannot afford to ignore

Time of India16-06-2025
In the blur of busy mornings, endless to-do lists, and late-night dinners, it is easy to brush off the little things—like feeling more tired than usual, needing a second glass of water more often, or barely noticing that a tiny wound is taking its time to heal. These moments slip by unnoticed, folded into the rhythm of everyday life. But sometimes, it is in these small shifts that the body starts to whisper—subtle signs that something deeper may be unfolding beneath the surface.
One of the most quietly persistent conditions that often begins this way is diabetes. Common, yes—but far from simple. It affects how the body manages blood sugar, often due to problems with insulin, the hormone that helps move glucose into our cells. When this process falters, sugar builds up in the blood, leading to long-term health issues if left unchecked.
There are three main types of diabetes:
Type 1
, which usually starts in childhood and needs insulin treatment for life
Gestational diabetes
, which happens during pregnancy and may go away after child birth
Type 2 diabetes
, the most common form which often develops in adults and is linked to lifestyle, diet and heredity. But it can also result from secondary causes such as chronic pancreatitis, Cushing's syndrome, or prolonged use of medications like steroids.
Prevalence of Type 2 diabetes is rising sharply in India due to shifting lifestyles, poor diets, physical inactivity, and rising obesity. According to the
Indian Council of Medical Research
(ICMR), over 101 million
1
people currently live with diabetes, and another 136 million
2
are pre-diabetic. The WHO estimates that around 77 million
3
Indian adults specifically have Type 2 diabetes, placing the country among those with the highest global burden. Yet despite these numbers, the condition often develops quietly, with subtle early signs that are easy to overlook. Recognising these signals early is crucial, as the real challenge lies not just in diagnosis, but in preventing the serious long-term risks Type 2 diabetes can bring.
To better understand the often-missed signs and why early screening is critical—especially for younger individuals with a family history—we spoke to Dr.
Ajay Agarwal
, Senior Director, Fortis Hospital, Noida. '
Some early signs include non-specific symptoms like increased thirst, frequent urination, and persistent hunger—even after meals. These form the classic triad of diabetes and should raise concern, particularly in those over 35,
' he said. '
Other indicators may be recurrent urinary infections, visual issues, slow-healing wounds, fatigue, and low energy.
' He stressed that early detection helps prevent serious complications such as kidney disease, retinopathy, and
neuropathy
, and also makes management simpler. '
While prediabetes can often be reversed with lifestyle changes, full-blown diabetes usually requires multiple medications, which can reduce compliance. Early diagnosis enables easier, more cost-effective treatment and significantly improves long-term outcomes.
'
Type 2 diabetes develops gradually and so do its complications. While these health risks may take years to surface, being aware of them early and managing blood sugar effectively, for example, by regularly monitoring at home with a good quality
glucometer machine
can greatly reduce their impact. Here are some common long-term health concerns linked to unmanaged Type 2 diabetes:
Cardiovascular health
: Diabetes can increase the risk of heart attacks, strokes, and peripheral artery disease by damaging blood vessels over time.
Kidney failure
: Chronic high blood sugar can silently lead to end-stage kidney disease, often requiring dialysis or transplant.
Nerve damage (Neuropathy)
: Starts with numbness or pain in feet and hands and may lead to digestive problems, sexual dysfunction, and even 'silent' heart attacks.
Vision loss
: Diabetic retinopathy is now one of the leading causes of blindness.
Amputations
: Poor circulation and nerve damage may cause ulcers and infections that go unnoticed—making diabetes the top cause of non-traumatic limb loss.
Other risks
: These include cognitive decline, increased risk of infections, and severe fatty liver disease.
On the long-term impact of unmanaged diabetes, Dr. Agarwal added, '
Chronic high blood sugar acts like a systemic poison, silently damaging blood vessels and nerves. The complications—from heart disease to kidney failure and diabetic foot—can be life-altering. Prevention of complications starts with early control of Diabetes.
'
The good news is that monitoring today doesn't need to be complicated or painful. With the availability of gentle lancing devices,
smart glucometer machines
, and user-friendly
digital tools
, people can track their sugar levels easily from home.
Highlighting the critical role of monitoring, Dr. Agarwal shared, '
Consistent glucose blood sugar monitoring using RBS (random blood sugar) charting and 3-monthly HbA1c testing is key. It keeps patients motivated and in control, while also giving doctors valuable insights into patients' glycemic profile.
' He further explained the evolving approach in clinical practice, '
We now recommend a 7-point blood sugar profile for many patients, which involves checking blood sugar levels before and after meals, as well as at bedtime. It's great information for the doctor and helps us tailor the treatment.
' Emphasising how monitoring directly informs risk assessment, Dr. Agarwal added, '
A newly diagnosed diabetic with an HbA1c of 10 worries me far more than someone with well-managed diabetes for 20 years and an HbA1c of 7. Regular and structured self-monitoring of blood glucose (SMBG) helps us catch before they escalate.
'
Because Type 2 diabetes develops slowly and its complications even more so, prevention and timely care are our most powerful allies. This is where lifestyle plays a crucial role. Eating balanced meals, staying active, maintaining a healthy weight, and blood sugar monitoring regularly—even when asymptomatic—can significantly delay or prevent diabetes. '
Lifestyle changes like losing 5–7% body weight, eating whole foods with fewer refined carbs, and exercising 150 minutes a week can dramatically reduce insulin resistance,
' says Dr. Agarwal. '
In people with a family history of diabetes, these habits, combined with regular monitoring with a
glucometer machine
at home, can delay or prevent diabetes altogether
', he added.
On the importance of early screening, especially for younger adults, Dr. Agarwal stresses, '
For adults in their 30s and 40s with a family history, screening is non-negotiable—even if they feel fine. A simple HbA1c test every 1–3 years can detect issues early. And regardless of results, adopting preventive habits is essential. I would also highlight women with gestational diabetes as a key group. Continuous glucose monitoring and Oral Glucose Tolerance Testing during pregnancy—once at the first consultation and again between 24–28 weeks—can help avoid dangerous complications
.'
Living with or working to prevent Type 2 diabetes is not about living in fear, but about understanding, care, and the quiet power of small, steady steps. It is a journey shaped not by perfection, but by progress. A journey that begins with staying curious about your health, asking questions, and making mindful choices each day. By approaching this path with patience and compassion, you not only support your own well-being but also create space for a healthier tomorrow for those around you.
References -
https://www.pib.gov.in/PressReleasePage.aspx?PRID=1944600
https://www.who.int/india/diabetes#:~:text=In India, there are estimated,developing diabetes in near future).
https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/diabetes-type-2
https://www.icmr.gov.in/icmrobject/custom_data/pdf/resource-guidelines/ICMR_GuidelinesType2diabetes2018_0.pdf
https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

IPV launches $110 mn angel fund in GIFT City to tap global startup capital
IPV launches $110 mn angel fund in GIFT City to tap global startup capital

Business Standard

time4 minutes ago

  • Business Standard

IPV launches $110 mn angel fund in GIFT City to tap global startup capital

Angel investment platform Inflection Point Ventures (IPV) on Thursday announced the launch of a $110 million Category I Angel Fund—IPV International—under the International Financial Services Centres Authority (IFSCA) framework at GIFT City. The fund will lead or participate in early-stage to pre-Series A funding rounds, with investment ticket sizes ranging from $100,000 to $1 million. The fund recorded its first close in April. First investment in Singapore's Cellivate Technologies IPV International has already made its maiden investment in Singapore-based deeptech startup Cellivate Technologies. The company is developing an ethical and scalable alternative to fetal bovine serum using magnetic stimulation, targeting applications across biotech, pharma, and adjacent sectors. 'A presence in GIFT City enables us to scale beyond national borders, engage with global startup ecosystems, and remain aligned with the rapidly shifting dynamics of the venture capital and private equity markets,' said Vinay Bansal, Founder and CEO of IPV. Bansal added that the fund has attracted significant interest not just from Indians and NRIs but also from non-Indian investors looking to enter India's booming startup ecosystem, with the GIFT City framework providing a favourable gateway. Backed by 50 successful exits, IPV aims to scale globally 'With a proven track record including 50 successful exits from a portfolio of over 220 startups, IPV is now set to leverage this experience and scale its platform to reach both national and international investors through IPV International,' said Mitesh Shah, Co-founder of IPV. In addition to IPV International, the firm has launched a $50 million Category II venture capital fund—Physis Capital—to back Pre-Series A to Series B growth-stage startups. The fund has so far invested in six startups, with several other deals in advanced stages. 'By leveraging the global access provided by the GIFT City platform, we're now well-positioned to invest in innovative ventures across international markets, enhancing both portfolio diversification and investor value,' said Ankur Mittal, Co-founder of IPV.

City leads in Ayushman Vay Vandan scheme
City leads in Ayushman Vay Vandan scheme

Time of India

time18 minutes ago

  • Time of India

City leads in Ayushman Vay Vandan scheme

Kanpur: Kanpur Nagar has emerged as a frontrunner in implementing the Prime Minister Ayushman Vay Vandan scheme, with around 61,000 senior citizens aged 70 and above receiving Ayushman cards in the past six months. Tired of too many ads? go ad free now Describing the scheme as a 'revolutionary step in health conservation', district magistrate Jitendra Pratap Singh said it offers critical health coverage of up to Rs 5 lakh to senior citizens, enabling access to free treatment for serious ailments. A total of 228 hospitals in the district have been empanelled under the scheme to provide cashless treatment. "The scheme is a major relief for the elderly who are often denied insurance coverage or are subjected to stringent conditions by private insurance companies," Singh said. "Now, diseases such as heart ailments, cancer, kidney failure, and stroke are being treated free of cost under this initiative." The DM reiterated that the scheme does not require any income certificate or ration card. "Any Indian citizen aged 70 or above is eligible. Only an Aadhaar card is needed to avail the benefit," the DM said, adding that the scheme also ensures portability, allowing beneficiaries to avail treatment anywhere in the country. Treatment covered under the Ayushman card includes heart surgeries like bypass and valve replacement, pacemaker implants, cancer therapies including chemotherapy and radiotherapy, brain tumour and stroke care, neurosurgeries, dialysis, orthopaedic and ENT surgeries, among others. "Our goal is to ensure that no eligible elderly citizen is left out," Singh said.

Indian firms aim to gorge on weight-loss drugs
Indian firms aim to gorge on weight-loss drugs

Hindustan Times

time34 minutes ago

  • Hindustan Times

Indian firms aim to gorge on weight-loss drugs

Until recently, Indians had few safe ways of joining the global craze for weight-loss drugs. Some smuggled them into the country when returning home from abroad; others chanced it with bootlegged versions from Dubai. But in March Mounjaro, a weight-loss drug from Eli Lilly, an American pharmaceutical giant, became legally available in India. In June Wegovy, a drug from Novo Nordisk, a Danish firm, followed. Demand is surging. Though Indians are on average slimmer than people in most other countries, the obese population is one of the largest in the world, along with America's and China's. In Delhi, every fourth resident has Type 2 diabetes. Between 2021 and 2024 Indian sales of weight-loss drugs grew five-fold to $72m. India's market could soon grow to $1bn, predicts Jefferies, an investment bank. This may be a modest share of the $24bn in annual global sales of weight-loss drugs. But as the global market is set to rocket to $150bn in annual sales in the next decade, industry insiders see India as a juicy target. Mounjaro was an instant hit: consumption tripled from March to April, according to one industry tracker. Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper versions of an inferior first-generation injectable, liraglutide. Sun Pharma, India's biggest drugs company, hopes to launch its own jab in five years. The Indian market is especially lucrative because those who most need to lose weight are also best placed to pay up. In America, poorer people tend to be fatter. But in India obesity peaks in the most prosperous southern regions and is more common among urban than rural populations. The university-educated are more likely to be obese, too. Indeed, the real boom will come next year. That is when the patent for semaglutide, the active ingredient in Ozempic and Wegovy, expires in India. The country's generics giants, such as Cipla and Lupin, will sprint to produce knock-offs. But to cash in on home turf, Indian drug firms need to beat foreign rivals by adapting a global blockbuster to Indian realities. The first is cost. Starting at around $200 a month, Eli Lilly and Novo Nordisk's Indian offering can cost as little as a fifth of their prices in America. But a year's supply of Mounjaro or Wegovy for a single Indian can still end up being roughly equivalent to the country's GDP per person. Indian generics will slash that figure. Some analysts predict a 95% nosedive. Second, South Asians are unusually genetically predisposed to fatty-liver disease. Novo Nordisk's clinical trials suggest semaglutide might reduce it by 37%. Delivering a drug that caters to the quirks of Indian physiology gives Novo Nordisk a head start. Buckle up Finally, consider logistics. Tirzepatide and semaglutide, the active ingredients in Eli Lilly and Novo Nordisk's products, respectively, are injectables. The jabs require cold storage. That is a tough ask in a hot country with patchy logistics chains. India's Mankind Pharma is expecting trial results by the end of 2025 for what would become India's first oral weight-loss drug that could rival injectables. Both Eli Lilly and Novo Nordisk hope to enter this race with their own versions next year. Whoever makes a good weight-loss pill will prosper, especially in rural India. India is the world's biggest supplier of generic drugs, meeting about 20% of global demand. Low- and middle-income countries across Africa, Latin America and South-East Asia have some of the fastest-rising diabetes rates in the world. Dr Reddy's, an Indian pharma giant, plans to launch a generic version of Wegovy in 87 countries when the patent expires next year. The company is targeting Brazil, Turkey and other emerging markets. India also supplies nearly half the generic drugs Americans consume. For now, America levies no tariffs on them. That could change before American patents start expiring in the next decade. David Ricks, Eli Lilly's CEO, has warned that Donald Trump's tariffs could jack up the price of Indian generics. Mr Trump has spoken of slapping 200% tariffs on pharmaceuticals. On July 30th he threatened a 25% general tariff on India and an unspecified 'penalty' for its stances on trade and Russia. If Indian pharma escapes the fallout, it might yet make America skinny again. Stay on top of our India coverage by signing up to Essential India, our free weekly newsletter.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store